↓ Skip to main content

Dove Medical Press

Article Metrics

Update on imatinib for gastrointestinal stromal tumors: duration of treatment

Overview of attention for article published in OncoTargets and therapy, July 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
29 Mendeley
Title
Update on imatinib for gastrointestinal stromal tumors: duration of treatment
Published in
OncoTargets and therapy, July 2013
DOI 10.2147/ott.s31260
Pubmed ID
Authors

Charlotte Benson, Mark Linch, Jeroen Claus

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the gastrointestinal tract, with transformation typically driven by activating mutations of c-KIT and less commonly platelet-derived growth factor receptor alpha (PDGFRA). Successful targeting of c-KIT and PDGFRA with imatinib, a tyrosine kinase inhibitor (TKI), has had a major impact in advanced GIST and as an adjuvant and neoadjuvant treatment. If treatment with imatinib fails, further lines of TKI therapy have a role, but disease response is usually only measured in months, so strategies to maximize the benefit from imatinib are paramount. Here, we provide an overview of the structure and signaling of c-KIT coupled with a review of the clinical trials of imatinib in GIST. In doing so, we make recommendations about the duration of imatinib therapy and suggest how best to utilize imatinib in order to improve patient outcomes in the future.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 3%
Belgium 1 3%
Unknown 27 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 21%
Student > Ph. D. Student 5 17%
Student > Bachelor 4 14%
Student > Doctoral Student 2 7%
Student > Master 2 7%
Other 6 21%
Unknown 4 14%
Readers by discipline Count As %
Medicine and Dentistry 13 45%
Agricultural and Biological Sciences 6 21%
Biochemistry, Genetics and Molecular Biology 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Chemistry 1 3%
Other 0 0%
Unknown 5 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2013.
All research outputs
#3,547,756
of 4,507,144 outputs
Outputs from OncoTargets and therapy
#264
of 401 outputs
Outputs of similar age
#79,730
of 100,616 outputs
Outputs of similar age from OncoTargets and therapy
#14
of 17 outputs
Altmetric has tracked 4,507,144 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 401 research outputs from this source. They receive a mean Attention Score of 1.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 100,616 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.